Pharma Pulse 4/4/25: What Racial Color-Blindness Means for Trial Participation, Insights from the 2025 Pharmacy in Focus Report & more

What Does Racial Color-Blindness Mean for Clinical Trial Participation?

Research collaboration between Tufts and the Society for Clinical Research Sites explores the prevalence of this belief in healthcare.

The GLP-1 Conundrum: Insights from the 2025 Pharmacy in Focus Report

Pharmacists play a crucial role in educating patients on proper administration and adherence to GLP-1 treatments.

Pharma’s Tariff Reprieve Will Be Temporary as More Levies Loom

The drug industry won a reprieve from sweeping tariffs announced by President Donald Trump on Wednesday, though it could be short-lived as the White House moves forward with plans for future levies on pharmaceutical imports.

Unlearn and remynd Partner on Alzheimer’s Study to Strengthen Confidence in Early Clinical Signals Using Digital Twins

Unlearn has announced results from a collaboration with remynd. The results were shared at the 2025 Alzheimer’s & Parkinson’s Drug Development Summit in Boston. The collaboration focused on remynd’s Phase IIa clinical trial of REM127, an investigational, first-generation small molecule therapy targeting septins in patients with mild-to-moderate Alzheimer’s Disease (AD). The study enrolled a limited number of participants and measured changes in AD biomarkers over a short treatment window.

Artiva Biotherapeutics on LinkedIn

Our CEO Fred Aslan sat down with Pharmaceutical Executive to discuss Artiva’s allogeneic NK cell therapies. In this five-part interview series, he shares insights on our dual clinical trial strategy and how AlloNK® may improve the treatment of serious autoimmune diseases by providing a deep B-cell depletion with a better tolerability profile.

Key topics covered:

🔹 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗻𝗴 𝗔𝗹𝗹𝗼𝗡𝗞 𝗘𝗳𝗳𝗶𝗰𝗮𝗰𝘆: How we are advancing AlloNK as a novel treatment across across autoimmune diseases https://lnkd.in/ggMk2iMb

🔹 “𝗜𝗺𝗺𝘂𝗻𝗲 𝗥𝗲𝘀𝗲𝘁” 𝗶𝗻 𝗦𝗟𝗘/𝗟𝗡: Our NK cell therapy approach in systemic lupus erythematosus / lupus nephritis https://lnkd.in/g28JR_nW

🔹 𝗔𝗿𝘁𝗶𝘃𝗮’𝘀 𝗔𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝗧𝗿𝗶𝗮𝗹𝘀: A closer look at our ongoing clinical programs https://lnkd.in/gJ2xG6nC

🔹𝗗𝘂𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆: Balancing company-sponsored and investigator-initiated trials to maximize clinical insights https://lnkd.in/gNauYshM

🔹 𝗙𝗗𝗔 𝗙𝗮𝘀𝘁 𝗧𝗿𝗮𝗰𝗸: The impact of Fast Track designation on the development of AlloNK https://lnkd.in/gD_CavQ5

Thank you to Miranda Schmalfuhs for showcasing the innovation and momentum behind Artiva’s work in NK cell therapy for autoimmune disease!

#AlloNK #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs